Lorenzo A CalÃ²

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6000763/publications.pdf

Version: 2024-02-01

		109321	144013
251	4,649	35	57
papers	citations	h-index	g-index

252	252	252	4601
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tracing angiotensin II's yin-yang effects on cardiovascular-renal pathophysiology. Minerva Medica, 2023, 114, .	0.9	5
2	Genotypeâ€“phenotype correlation in Gordonâ€™s syndrome: report of two cases carrying novel heterozygous mutations. Journal of Nephrology, 2022, 35, 859-862.	2.0	5
3	Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach. Journal of Clinical Medicine, 2022, 11, 402.	2.4	1
4	Systemic anticoagulation and new biocompatible dialyzers in the different kidney replacement techniques: More doubts than certainties. Artificial Organs, 2022, 46, 516-517.	1.9	0
5	Parathyroid hormone and phosphate homeostasis in patients with Bartter and Gitelman syndrome: an international cross-sectional study. Nephrology Dialysis Transplantation, 2022, 37, 2474-2486.	0.7	5
6	The counter-regulatory arm of the renin-angiotensin system and COVID-19: insights from Gitelman's and Bartter's syndromes. Journal of Hypertension, 2022, 40, 648-649.	0.5	4
7	Rare genetic tubulopathies Gitelman's and Bartter's syndromes and their naturally occurring protection from COVID-19. Minerva Medica, 2022, , .	0.9	2
8	Impaired ACE2 glycosylation and protease activity lowers COVIDâ€19 susceptibility in Gitelman's and Bartter's syndromes. Journal of Internal Medicine, 2022, 291, 522-524.	6.0	7
9	In vitro use of standard fluid infusion central venous catheter for slow continuous ultrafiltration feasibility assessment. Artificial Organs, 2022, , .	1.9	1
10	MO041: Impaired ACE2 glycosylation and protease activity lowers susceptibility to SARS-COV-2 infection in Gitelman/Bartter syndromes. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
11	MO024: Effect of green tea on top of enzyme replacement therapy in patients with Fabry disease: a molecular biology approach. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
12	Two unusual cases of Gitelmanâ€™s syndrome with a complex inheritance: how the phenotype can help interpret the genotype: lesson for the clinical nephrologist. Journal of Nephrology, 2021, 34, 1327-1330.	2.0	0
13	Switching to HFR Supra resolved refractory itch and quality of life in a chronic dialysis with liver transplant patient. Artificial Organs, 2021, 45, 320-321.	1.9	5
14	Diagnosis and management of Bartter syndrome: executive summary of the consensus and recommendations from the European Rare Kidney Disease Reference Network Working Group for Tubular Disorders. Kidney International, 2021, 99, 324-335.	5.2	53
15	Genetics and phenotypic heterogeneity of Dent disease: the dark side of the moon. Human Genetics, 2021, 140, 401-421.	3.8	32
16	Clinical Evidence for the Choice of the Direct Oral Anticoagulant in Patients with Atrial Fibrillation According to Creatinine Clearance. Pharmaceuticals, 2021, 14, 279.	3.8	6
17	Going to war with COVID-19: Strategies for SARS-CoV-2 management in the Padua Nephrology and Dialysis Unitâ€™s hemodialysis facility. Clinical Nephrology, 2021, 95, 151-156.	0.7	2
18	On the imbalanced protective arm of RAS in COVIDâ€19: Lesson from rare genetic tubulopathies. International Journal of Clinical Practice, 2021, 75, e14075.	1.7	0

#	Article	IF	Citations
19	MO073HISTOLOGICAL PREDICTORS OF PROTEINURIA AND RENAL OUTCOMES IN PRIMARY MEMBRANOUS NEPHROPATHY: IS INTERSTITIAL FIBROSIS THE MAIN CHARACTER?. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
20	MO022EVALUATION OF THE EFFECT OF TOLVAPTAN ON OXIDATIVE STRESS IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD). Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
21	ACE2 and SARS-CoV-2 Infection Risk: Insights From Patients With Two Rare Genetic Tubulopathies, Gitelman's and Bartter's Syndromes. Frontiers in Medicine, 2021, 8, 647319.	2.6	9
22	MO012ACE2 AND SARS-COV-2 INFECTION RISK: INSIGHTS FROM PATIENTS WITH TWO RARE GENETIC TUBULOPATHIES, GITELMANâ€˜S AND BARTTERâ€™S SYNDROMES. Nephrology Dialysis Transplantation, 2021, 36 .	0.7	0
23	Light chain deposition disease with low glomerular proteinuria and multiple myeloma: If you search you find. Nephrology, 2021, 26, 842-843.	1.6	0
24	The Pivotal Role of Oxidative Stress in the Pathophysiology of Cardiovascular-Renal Remodeling in Kidney Disease. Antioxidants, 2021, 10, 1041.	5.1	17
25	Oxidative stress, inflammation, and peritoneal dialysis: A molecular biology approach. Artificial Organs, 2021, 45, 1202-1207.	1.9	11
26	Padova University nephrology unitâ€™s peritoneal dialysis management during the COVID-19 pandemic. Clinical Nephrology, 2021, 96, 60-62.	0.7	0
27	The Dietary Approach to the Treatment of the Rare Genetic Tubulopathies Gitelmanâ€™s and Barterâ€™s Syndromes. Nutrients, 2021, 13, 2960.	4.1	3
28	Impact of different hemodiafiltration solutions on ionemia in long-term CRRT. International Journal of Artificial Organs, 2021, 44, 807-815.	1.4	3
29	Far di NecessitÃ VirtÃ¹, using rare tubulopathies, Gitelmanâ€™s and Barterâ€™s syndromes, to inform the fight against COVID-19. Journal of Nephrology, 2021, 34, 281-283.	2.0	3
30	Efficacy of weekly administration of cholecalciferol on parathyroid hormone in stable kidney-transplanted patients with CKD stage 1â€“3. Clinical Chemistry and Laboratory Medicine, 2021, 59, 343-351.	2.3	0
31	Massive lung calcifications in a four times renal transplanted patient: the fight against dialysis, hyper and hypoparathyroidism. Minerva Endocrinology, 2021, , .	1.1	0
32	Cornea verticillata in Fabry disease: a comparative study between slit-lamp examination and in vivo corneal confocal microscopy. British Journal of Ophthalmology, 2020, 104, 718-722.	3.9	10
33	Regional citrate anticoagulation dose for continuous renal replacement therapy. Nephrology, 2020, 25, 361-361.	1.6	3
34	Could nutritional therapy take us further in our approaches to Fabry disease?. Nutrition, 2020, 72, 110664.	2.4	8
35	Ultrasound for the Clinical Management of Vascular Access Cannulation and Needle Position in Hemodialysis Patients. Ultrasound in Medicine and Biology, 2020, 46, 455-459.	1.5	7
36	P1190OXIDATIVE STRESS AND INFLAMMATION IN PERITONEAL DIALYSIS: DANGEROUS AND TO BE SOLVED. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0

#	Article	IF	Citations
37	Letter: ACE2, Rho kinase inhibition and the potential role of vitamin D against COVIDâ€19. Alimentary Pharmacology and Therapeutics, 2020, 52, 577-578.	3.7	11
38	Are the Clinical Presentations (Phenotypes) of Gitelmanâ€™s and Bartterâ€™s Syndromes Gene Mutations Driven by Their Effects on Intracellular pH, Their â€œpHâ€•Enotype?. International Journal of Molecular Sciences, 2020, 21, 5660.	4.1	6
39	Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093458.	3.2	7
40	P0084DIGENIC INHERITANCE: TWO RARE CASES OF GITELMAN SYNDROME. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
41	ACE2 and prognosis of COVIDâ€19: Insights from Bartter's and Gitelman's syndromes patients. Journal of Medical Virology, 2020, 92, 2308-2309.	5.0	2
42	ROCK (RhoA/Rho Kinase) in Cardiovascularâ€“Renal Pathophysiology: A Review of New Advancements. Journal of Clinical Medicine, 2020, 9, 1328.	2.4	51
43	Rho kinase inhibitors for SARS-CoV-2 induced acute respiratory distress syndrome: Support from Bartterâ€™s and Gitelmanâ€™s syndrome patients. Pharmacological Research, 2020, 158, 104903.	7.1	9
44	Angiotensin-converting enzyme inhibitors, angiotensin II type 1 receptor blockers and risk of COVID 19: information from Bartter's and Gitelman's syndromes patients. Journal of Hypertension, 2020, 38, 1386.	0.5	5
45	Intravenous ferric carboxymaltose for iron deficiency anemia in dialysis patients: Effect of a new protocol adopted for a hemodialysis limited assistance center. Therapeutic Apheresis and Dialysis, 2020, 24, 642-647.	0.9	2
46	High Blood Pressure Is Associated with Tubulointerstitial Damage along with Glomerular Damage in Glomerulonephritis. A large Cohort Study. Journal of Clinical Medicine, 2020, 9, 1656.	2.4	5
47	Rho Kinase Activity, Connexin 40, and Atrial Fibrillation: Mechanistic Insights from End-Stage Renal Disease on Dialysis Patients. Journal of Clinical Medicine, 2020, 9, 165.	2.4	7
48	Evaluating Nephrocheck^{Â®} as a Predictive Tool for Acute Kidney Injury . International Journal of Nephrology and Renovascular Disease, 2020, Volume 13, 85-96.	1.8	26
49	From protein uptake to Dent disease: An overview of the CLCN5 gene. Gene, 2020, 747, 144662.	2.2	27
50	A Continuous Renal Replacement Therapy Protocol for Patients with Acute Kidney Injury in Intensive Care Unit with COVID-19. Journal of Clinical Medicine, 2020, 9, 1529.	2.4	15
51	The Dialyzer Identification Code (DIC): A filter characteristics codification for dialyzer choice in renal replacement therapy. Artificial Organs, 2020, 44, 1220-1223.	1.9	3
52	Potential role of phytochemicals in metabolic syndrome prevention and therapy . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 1987-2002.	2.4	38
53	New insights on the renal protective effects of mineralocorticoid receptor antagonists. Journal of Hypertension, 2019, 37, 9-10.	0.5	1
54	Factors predicting influenza vaccination adherence among patients in dialysis: an Italian survey. Human Vaccines and Immunotherapeutics, 2019, 15, 2434-2439.	3.3	16

#	Article	IF	Citations
55	Bartter and Gitelman Syndromes. , 2019, , 713-721.		0
56	Rho kinase activity and atrial fibrillation. Journal of Hypertension, 2019, 37, 1096-1097.	0.5	1
57	Proinflammatory/profibrotic effects of aldosterone in Gitelmanâ€™s syndrome, a human model opposite to hypertension. Journal of Endocrinological Investigation, 2019, 42, 521-526.	3.3	2
58	Is heme oxygenase-1 turning out to be a key positive regulator for oxidative stress?. Minerva Medica, 2019, 110, 88-90.	0.9	0
59	Oxidative Stress in Hypertension and Cardiovascular-Renal Remodeling: Focus on the Renin-Angiotensin-Aldosterone System. , 2019, , 581-596.		0
60	Searching for an additional treatment to slowing the progression of Fabry disease. Minerva Medica, 2019, 110, 176-178.	0.9	0
61	Comment on â€œVitamin E supplementation improves high-density lipoprotein and endothelial functions in end-stage kidney disease patients undergoing hemodialysisâ€•by Mune et al. Clinical Nephrology DOI 10.5414/CN109197 e-pub: April 9, 2018. Clinical Nephrology, 2019, 91, 323-324.	0.7	0
62	Is exercise becoming a danger for our health? The complex relationship between exercise and atrial fibrillation. European Journal of Preventive Cardiology, 2018, 25, 621-623.	1.8	5
63	GÎ±q/p63RhoGEF interaction in RhoA/Rho kinase signaling: investigation in Gitelmanâ€™s syndrome and implications with hypertension. Journal of Endocrinological Investigation, 2018, 41, 351-356.	3.3	4
64	SP021CARDIOVASCULAR-RENAL REMODELING IN FABRY DISEASE: POSSIBLE INVOLVEMENT OF OXIDATIVE STRESS. A MOLECULAR BIOLOGY APPROACH. Nephrology Dialysis Transplantation, 2018, 33, i354-i354.	0.7	0
65	Oxidative Stress and Cardiovascular-Renal Damage in Fabry Disease: Is There Room for a Pathophysiological Involvement?. Journal of Clinical Medicine, 2018, 7, 409.	2.4	17
66	Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling?. PLoS ONE, 2018, 13, e0204618.	2.5	24
67	A unique case of rapidly progressive glomerulonephritis following dexamethasone/bortezomib/thalidomide treatment for myeloma. Nephrology, 2018, 23, 1065-1067.	1.6	0
68	Oxidative stress â€“ chronic kidney disease â€“ cardiovascular disease: A vicious circle. Life Sciences, 2018, 210, 125-131.	4.3	77
69	Gitelmanâ€™s Syndrome: characterization of a novel c.1181G>A point mutation and functional classification of the known mutations. Hypertension Research, 2018, 41, 578-588.	2.7	4
70	Smoking causes atrial fibrillation? Further evidence on a debated issue. European Journal of Preventive Cardiology, 2018, 25, 1434-1436.	1.8	4
71	Cigarette Smoking is Associated with Decreased Bone Gla-protein (BGP) Levels in Hemodialysis Patients. Current Vascular Pharmacology, 2018, 16, 603-609.	1.7	6
72	Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. Journal of Hypertension, 2017, 35, 205-212.	0.5	93

#	Article	IF	Citations
73	The Time has Come for Systematic Screening for Primary Aldosteronism inÂAllÂHypertensives â^—. Journal of the American College of Cardiology, 2017, 69, 1821-1823.	2.8	15
74	Magnesium, cardiovascularâ€“renal disease and the Gitelman's syndrome paradox. Journal of Hypertension, 2017, 35, 1122-1124.	0.5	2
75	Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2017, 91, 24-33.	5.2	230
76	Is there an increased heme oxygenase-1 behind the antioxidant effects of green tea on blood pressure and sympathoexcitation reduction?. Journal of Hypertension, 2017, 35, 1718-1719.	0.5	1
77	In Patients with Chronic Kidney Disease Short Term Blood Pressure Variability is Associated with the Presence and Severity of Sleep Disorders. Kidney and Blood Pressure Research, 2017, 42, 804-815.	2.0	14
78	Pathophysiology of Post Transplant Hypertension in Kidney Transplant: Focus on Calcineurin Inhibitors Induced Oxidative Stress and Renal Sodium Retention and Implications with RhoA/Rho Kinase Pathway. Kidney and Blood Pressure Research, 2017, 42, 676-685.	2.0	16
79	Thymoma-associated renal pathology: Is renal biopsy always necessary? A clinical problem-solving exercise and teaching example for physicians. International Urology and Nephrology, 2017, 49, 1893-1895.	1.4	0
80	A Very Unique Case of Boric Acid Intoxication With Very High-magnitude Rhabdomyolysis. Iranian Journal of Kidney Diseases, 2017, 11, 256-257.	0.1	0
81	Assessing the Relationship of Angiotensin II Type 1 Receptors with Erythropoietin in a Human Model of Endogenous Angiotensin II Type 1 Receptor Antagonism. CardioRenal Medicine, 2016, 6, 16-24.	1.9	6
82	To reconsider (limit) the use of phosphate based food and beverages additives. A real need for health preservation. Clinical Nutrition, 2016, 35, 240.	5.0	3
83	Endothelinâ€1 Drives Epithelialâ€Mesenchymal Transition in Hypertensive Nephroangiosclerosis. Journal of the American Heart Association, 2016, 5, .	3.7	34
84	Increased rho kinase activity in mononuclear cells of dialysis and stage 3â€“4 chronic kidney disease patients with left ventricular hypertrophy: Cardiovascular risk implications. Life Sciences, 2016, 148, 80-85.	4.3	27
85	Uric acid and cardiovascular-renal disease risk. Insights from a human model opposite to hypertension. International Journal of Cardiology, 2016, 212, 18-19.	1.7	4
86	Assessment of the Quantitative Value Usefulness of the Aldosterone-Renin Ratio (ARR) for Primary Aldosteronism (AQUARR) Study. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 19-23.	2.2	3
87	Heme oxygenase-1 in type 2 diabetes: from cell first-line defense to early marker of diabetic nephropathy. Minerva Medica, 2016, 107, 123-4.	0.9	3
88	The association of systemic oxidative stress with insulin resistance: mechanistic insights from studies in <scp>B</scp>artter's and <scp>G</scp>itelman's syndromes. Clinical Endocrinology, 2015, 83, 994-995.	2.4	6
89	Intensive Home Hemodialysis: An Eye at the Past Looking for the Hemodialysis of the Future. Artificial Organs, 2015, 39, 736-740.	1.9	3
90	Systolic and diastolic short-term blood pressure variability and its determinants in patients with controlled and uncontrolled hypertension: A retrospective cohort study. Blood Pressure, 2015, 24, 124-129.	1.5	15

#	Article	IF	Citations
91	Hypomagnesaemia, cardiovascularâ€“renal negative effects and Gitelman's syndrome: A paradox awaiting resolution. International Journal of Cardiology, 2015, 198, 106-107.	1.7	0
92	Mechanistic approach to the pathophysiology of target organ damage in hypertension from studies in a human model with characteristics opposite to hypertension: Bartterâ€™s and Gitelmanâ€™s syndromes. Journal of Endocrinological Investigation, 2015, 38, 711-716.	3.3	18
93	Angiotensin II and Cardiovascular-Renal Remodelling in Hypertension: Insights from a Human Model Opposite to Hypertension. High Blood Pressure and Cardiovascular Prevention, 2015, 22, 215-223.	2.2	10
94	Bartter/Gitelman syndromes as a model to study systemic oxidative stress in humans. Free Radical Biology and Medicine, 2015, 88, 51-58.	2.9	13
95	The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1245-1250.	1.7	26
96	Treatment of atherosclerotic renovascular hypertension: review of observational studies and a meta-analysis of randomized clinical trials. Nephrology Dialysis Transplantation, 2015, 30, 541-553.	0.7	34
97	Relationship between NOX4 level and angiotensin II signaling in Gitelman's syndrome. Implications with hypertension. International Journal of Clinical and Experimental Medicine, 2015, 8, 7487-96.	1.3	1
98	Rho kinase, oxidative stress, ACE2/Ang 1-7 and lung fibrosis. Minerva Medica, 2015, 106, 182-3.	0.9	1
99	Hemodiafiltration and reduction of inflammation in dialysis patients. Kidney International, 2014, 86, 651.	5.2	3
100	â€œOf coronary arteries and menâ€: the fight of a dialysis patient against his coronary arteries. Renal Failure, 2014, 36, 627-630.	2.1	0
101	Increased <scp>RBP</scp>4 in a human model of activated antiâ€atherosclerotic and antiremodelling defences. European Journal of Clinical Investigation, 2014, 44, 567-572.	3.4	14
102	Ultrafiltration for the treatment of congestion: a window into the lung for a better caress to the heart. Nephrology Dialysis Transplantation, 2014, 29, 1335-1341.	0.7	7
103	Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients. Journal of Hypertension, 2014, 32, 331-338.	0.5	55
104	Hypokalemia in Thyrotoxic Periodic Paralysis: Implication for Nephrology Practice. Blood Purification, 2014, 37, 188-188.	1.8	0
105	Understanding the mechanisms of angiotensin II signaling involved in hypertension and its long-term sequelae. Journal of Hypertension, 2014, 32, 2109-2119.	0.5	53
106	Molecular biology based assessment of green tea effects on oxidative stress and cardiac remodelling in dialysis patients. Clinical Nutrition, 2014, 33, 437-442.	5.0	29
107	Angiotensin II Type 2 Receptor Effects: Lesson From a Human Model of Vascular Hyporeactivity. Letter Regarding Kemp et al. Circulation Research, 2014, 115, e24-5.	4.5	1
108	Apparent mineralcorticoid excess syndrome, an often forgotten or unrecognized cause of hypokalemia and hypertension: Case report and appraisal of the pathophysiology. Blood Pressure, 2014, 23, 189-192.	1.5	12

#	Article	IF	Citations
109	Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients. Journal of Hypertension, 2014, 32, 193-199.	0.5	17
110	Dissociating angiotensin 1-9 anticardiovascular remodeling effects from those on blood pressure. Journal of Hypertension, 2014, 32, 1718-1719.	0.5	2
111	Aldosterone-induced oxidative stress. Journal of Hypertension, 2014, 32, 2280-2281.	0.5	4
112	Long-Term Proton Pump Inhibitor Use is Associated with Vascular Calcification in Chronic Kidney Disease: A Cross-Sectional Study Using Propensity Score Analysis. Drug Safety, 2013, 36, 635-642.	3.2	21
113	Daily green tea extract supplementation reduces prothrombotic and inflammatory states in dialysis patients. Journal of Functional Foods, 2013, 5, 1366-1371.	3.4	12
114	The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts. Mediators of Inflammation, 2013, 2013, 1-13.	3.0	208
115	Pelvicâ€“ureteric junction obstruction and hypertension with target organ damage: A case report and review of the literature. Blood Pressure, 2013, 22, 336-339.	1.5	1
116	Revascularization for atherosclerotic renal artery stenosis: another flawed son of the ASTRAL Study. Hypertension Research, 2013, 36, 85-86.	2.7	1
117	SIRT1, heme oxygenase-1 and NO-mediated vasodilation in a human model of endogenous angiotensin II type 1 receptor antagonism: implications for hypertension. Hypertension Research, 2013, 36, 873-878.	2.7	20
118	A very unusual case of hypokalaemia. CKJ: Clinical Kidney Journal, 2013, 6, 87-89.	2.9	3
119	Arterial hypertension and cardiovascular risk in HIV-infected patients. Journal of Cardiovascular Medicine, 2013, 14, 553-558.	1.5	17
120	Angiotensin II type 1 and type 2 receptor interplay in hypertension. Journal of Hypertension, 2013, 31, 1055-1056.	0.5	1
121	De Lapidibus podagra et chiragra in humano corpore productis (Rome, 1699): the contribution of Giovanni Battista Contoli to the description and classification of urinary tract stones. Journal of Nephrology, 2013, 26, 136-138.	2.0	3
122	Morbus dominorum: gout as the disease of lords. Journal of Nephrology, 2013, 26, 113-116.	2.0	2
123	Gitelmanâ€™s syndrome and pregnancy: new potential pathophysiological influencing factors, therapeutic approach and materno-fetal outcome. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 1511-1513.	1.5	16
124	Hyperparathyroidism Can Be Useful in the Identification of Primary Aldosteronism Due To Aldosterone-Producing Adenoma. Hypertension, 2012, 60, 431-436.	2.7	61
125	Calcitonin gene-related peptide, heme oxygenase-1, endothelial progenitor cells and nitric oxide-dependent vasodilation relationships in a human model of angiotensin II type-1 receptor antagonism. Journal of Hypertension, 2012, 30, 1406-1413.	0.5	13
126	Angiotensin II type 2 receptors mediating both vasoconstriction and vasodilation in humans. Journal of Hypertension, 2012, 30, 628-629.	0.5	0

#	Article	IF	Citations
127	Magnesium and Gitelman's Syndrome â€“ÂaÂparadox awaiting resolution. Magnesium Research, 2012, 25, 147-148.	0.5	0
128	Phosphate Content of Beverages in Addition to Food Phosphate Additives: Real and Insidious Danger for Renal Patients. , 2012, 22, 292-293.		10
129	<scp>L</scp> carnitine in hemodialysis patients. Hemodialysis International, 2012, 16, 428-434.	0.9	20
130	Hemodiafiltration With Online Regeneration of Ultrafiltrate: Effect on Hemeâ€Oxygenaseâ€1 and Inducible Subunit of Nitric Oxide Synthase and Implication for Oxidative Stress and Inflammation. Artificial Organs, 2011, 35, 183-187.	1.9	26
131	Salivary Glands: A New Player in Phosphorus Metabolism. , 2011, 21, 39-42.		22
132	Antihypertensive and antiremodeling effects of Rho kinase inhibition via activation of ACE2 pathway. Journal of Hypertension, 2011, 29, 1660-1661.	0.5	0
133	Molecular Biologyâ€Based Assessment of Vitamin Eâ€Coated Dialyzer Effects on Oxidative Stress, Inflammation, and Vascular Remodeling. Artificial Organs, 2011, 35, E33-9.	1.9	26
134	Bartterâ€™s and Gitelmanâ€™s diseases. Best Practice and Research in Clinical Rheumatology, 2011, 25, 637-648.	3.3	21
135	PLCÎ²1-SHP-2 complex, PLCÎ²1 tyrosine dephosphorylation and SHP-2 phosphatase activity: a new part of Angiotensin II signaling?. Journal of Biomedical Science, 2011, 18, 38.	7.0	2
136	EPO and HO-1 in cardiovascular and renal protection: just a common signaling pathway or a mechanistic link?. Nephrology Dialysis Transplantation, 2011, 26, 3416-3417.	0.7	1
137	Does p63RhoGEF, a new key mediator of angiotensin II signalling, play a role in blood pressure regulation and cardiovascular remodelling in humans?. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 634-636.	1.7	12
138	Treatment with Vitamin E-coated membrane dialysers and cardiovascular protection in dialysis patients. Nephrology Dialysis Transplantation, 2011, 26, 1754-1754.	0.7	0
139	Endothelial progenitor cells relationships with clinical and biochemical factors in a human model of blunted angiotensin II signaling. Hypertension Research, 2011, 34, 1017-1022.	2.7	22
140	Effect of olmesartan on oxidative stress in hypertensive patients. Mechanistic support to clinical trials derived evidence. Blood Pressure, 2011, 20, 376-382.	1.5	20
141	Treatment with Calcimimetic (Cinacalcet) Alters Epoetin Dosage Requirements in Dialysis Patients: Preliminary Report. Renal Failure, 2011, 33, 732-735.	2.1	11
142	Reduction of Hyperphosphatemia is Related with the Reduction of C-Reactive Protein in Dialysis Patients. Study in Sevelamer-Resistant Dialysis Patients Treated with Chitosan Chewing Gum as Salivary Phosphate Binder. Renal Failure, 2011, 33, 11-14.	2.1	7
143	Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies. Current Vascular Pharmacology, 2011, 9, 763-769.	1.7	22
144	Number and function of circulating endothelial progenitor cells and calcitonin gene-related peptide in hypertension: support from and opportunities in Bartter's and Gitelman's syndromes patients. Journal of Hypertension, 2010, 28, 2169-2170.	0.5	3

#	Article	IF	Citations
145	RGS2 expression and aldosterone: renin ratio modulate response to drug therapy in hypertensive patients. Journal of Hypertension, 2010, 28, 1104-1108.	0.5	16
146	Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. Journal of Hypertension, 2010, 28, 111-118.	0.5	44
147	Research update for articles published in EJCI in 2008. European Journal of Clinical Investigation, 2010, 40, 770-789.	3.4	1
148	HO-1 Attenuates Hypertension-Induced Inflammation/Oxidative Stress: Support From Bartter's/Gitelman's Patients. American Journal of Hypertension, 2010, 23, 936-936.	2.0	8
149	A rare cause of flank pain. CKJ: Clinical Kidney Journal, 2010, 3, 316-317.	2.9	0
150	Comment on:Hemodiafiltration in a critical dialysis patient with H1N1 influenza A. Renal Failure, 2010, 32, 902-902.	2.1	0
151	Comment on:Acute kidney injury and rhabdomyolysis: a role for the regulator of G-protein signaling (RGS)-2. Renal Failure, 2010, 32, 529-530.	2.1	2
152	The PGC1Â-PPARÂ-HO-1 system: supporting evidence from studies in Bartter's/Gitelman's syndromes. Cardiovascular Research, 2010, 86, 535-535.	3.8	0
153	Oxidative stress-related proteins in a Connâ€™s adenoma tissue. Relevance for aldosteroneâ€™s prooxidative and proinflammatory activity. Journal of Endocrinological Investigation, 2010, 33, 48-53.	3.3	21
154	ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: pathophysiological implications. Journal of Nephrology, 2010, 23, 472-7.	2.0	29
155	Obsessive-Compulsive and Post Traumatic Avoidance Symptoms Influence the Response to Antihypertensive Therapy: Relevance in Uncontrolled Hypertension. Pharmaceuticals, 2009, 2, 82-93.	3.8	1
156	Salivary Glands: A ‘Third Kidney’ for Phosphate Excretion in Kidney Disease?. Blood Purification, 2009, 28, 364-364.	1.8	2
157	Salivary Phosphate-Binding Chewing Gum Reduces Hyperphosphatemia in Dialysis Patients. Journal of the American Society of Nephrology: JASN, 2009, 20, 639-644.	6.1	66
158	Lâ€CARNITINE, INFLAMMATION AND HYPERTENSION. Nephrology, 2009, 14, 264-265.	1.6	2
159	High angiotensin II state without cardiac remodeling (Bartterâ€™s and Gitelmanâ€™s syndromes): Are angiotensin II type 2 receptors involved?. Journal of Endocrinological Investigation, 2009, 32, 832-836.	3.3	41
160	Salivary Phosphorus and Phosphate Content of Beverages: Implications for the Treatment of Uremic Hyperphosphatemia. , 2009, 19, 69-72.		21
161	A pheochromocytoma with normal clonidine-suppression test: how difficult the biochemical diagnosis?. Internal and Emergency Medicine, 2008, 3, 61-64.	2.0	1
162	Salivary Phosphate Secretion in Chronic Kidney Disease. , 2008, 18, 87-90.		37

#	Article	IF	Citations
163	Heme oxygenase-1 is an important modulator in limiting glucose-induced apoptosis in human umbilical vein endothelial cells. Life Sciences, 2008, 82, 383-392.	4.3	23
164	High phosphate content beverages in dialysis patients: Relevance for hyperphosphatemia and cardiovascular risk. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, e39-e40.	2.6	16
165	Absence of vascular remodelling in a high angiotensin-II state (Bartter's and Gitelman's syndromes): implications for angiotensin II signalling pathways. Nephrology Dialysis Transplantation, 2008, 23, 2804-2809.	0.7	55
166	EPO induces rise in serum ADMA but does not prevent the increase in NO release: the likely involvement of HO-1. Nephrology Dialysis Transplantation, 2008, 23, 3035-3036.	0.7	1
167	Silencing regulator of G protein signaling-2 (RGS-2) increases angiotensin II signaling: insights into hypertension from findings in Bartter's/Gitelman's syndromes. Journal of Hypertension, 2008, 26, 938-945.	0.5	42
168	Hypertension, Diabetes, Oxidative Stress, and Cardiovascular Remodeling: Making the Connection with p66shc. , 2008, , 279-291.		0
169	Carnitine-mediated improved response to erythropoietin involves induction of haem oxygenase-1: studies in humans and in an animal model. Nephrology Dialysis Transplantation, 2007, 23, 890-895.	0.7	22
170	NADPH oxidase subunits (NOX-1, p22phox, Rac-1) and tacrolimus-induced nephrotoxicity in a rat renal transplant model. Nephrology Dialysis Transplantation, 2007, 22, 2402-2402.	0.7	4
171	Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrology Dialysis Transplantation, 2007, 22, 1413-1419.	0.7	77
172	Phosphate Salivary Secretion in Hemodialysis Patients: Implications for the Treatment of Hyperphosphatemia. Nephron Physiology, 2007, 105, p52-p55.	1.2	30
173	RhoA/Rho-kinase pathway: much more than just a modulation of vascular tone. Evidence from studies in humans. Journal of Hypertension, 2007, 25, 259-264.	0.5	97
174	Aldosterone and Resistant Hypertension. Current Hypertension Reviews, 2007, 3, 143-147.	0.9	0
175	Blood Pressure Response After an Acute Stroke During Ambulatory Blood Pressure Monitoring. High Blood Pressure and Cardiovascular Prevention, 2007, 14, 49-50.	2.2	1
176	Autonomic Nervous System Function in Chronic Hypotension Associated With Bartter and Gitelman Syndromes. American Journal of Kidney Diseases, 2007, 49, 330-335.	1.9	8
177	A Role for Heme Oxygenase-1 in the Antioxidant and Antiapoptotic Effects of Erythropoietin: The Start of a Good News/Bad News Story?. Nephron Physiology, 2006, 103, 107-111.	1.2	21
178	Aldosterone and Refractory Hypertension: A Prospective Cohort Study. American Journal of Hypertension, 2006, 19, 373-379.	2.0	54
179	Antioxidant effect of l-carnitine and its short chain esters. International Journal of Cardiology, 2006, 107, 54-60.	1.7	143
180	Oxidative stress and post-transplant hypertension in pediatric kidney-transplanted patients. Journal of Pediatrics, 2006, 149, 53-57.	1.8	9

#	Article	IF	Citations
181	Walnuts Reduce Aortic ET-1 mRNA Levels in Hamsters Fed a High-Fat, Atherogenic Diet. Journal of Nutrition, 2006, 136, 428-432.	2.9	34
182	Reduced expression of regulator of G-protein signaling 2 (RGS2) in hypertensive patients increases calcium mobilization and ERK1/2 phosphorylation induced by angiotensin II. Journal of Hypertension, 2006, 24, 1115-1124.	0.5	122
183	The search for a link between inflammation and hypertensionâ€"contribution from Bartter's/Gitelman's syndromes. Nephrology Dialysis Transplantation, 2006, 21, 2340-2342.	0.7	6
184	Blood pressure in acute ischemic stroke and mortality: a study with noninvasive blood pressure monitoring. Blood Pressure Monitoring, 2006, 11, 199-205.	0.8	13
185	CARNITINE'S PROTECTIVE EFFECT ON OXIDATIVE STRESS IS MEDIATED BY HEME OXYGENASE-1. Nephrology, 2006, 11, 569-569.	1.6	1
186	Vascular tone control in humans: Insights from studies in Bartter's/Gitelman's syndromes. Kidney International, 2006, 69, 963-966.	5.2	68
187	â€˜The Heart Never Grows Better by â€˜â€˜AGEâ€™â€™; I Fear Rather Worse...â€™. Blood Purification, 2006, 24, 367-368.	1.7	1
188	Rho/Rho-kinase and C-reactive protein relationship in hypertension and atherosclerosis. Nephrology Dialysis Transplantation, 2006, 21, 1131-1132.	0.7	7
189	Early markers of inflammation in a high angiotensin II stateâ€"results of studies in Bartter's/Gitelman's syndromes. Nephrology Dialysis Transplantation, 2006, 21, 1697-1701.	0.7	16
190	Phosphate binders and management of hyperphosphataemia in end-stage renal disease. Nephrology Dialysis Transplantation, 2006, 21, 2065-2068.	0.7	25
191	Insulin Signaling, Glucose Metabolism, and the Angiotensin II Signaling System: Studies in Bartter's/Gitelman's syndromes. Diabetes Care, 2006, 29, 469-471.	8.6	25
192	Effect of Doxazosin on Oxidative Stress-Related Proteins in Benign Prostatic Hyperplasia. Urologia Internationalis, 2006, 76, 36-41.	1.3	10
193	Identification of the mineralocorticoid receptor in human spermatozoa. International Journal of Molecular Medicine, 2006, 18, 649-52.	4.0	7
194	Bartter's and Gitelman's syndromes: a confirm in humans of the utility of Rho kinase inhibition for cardiovascular protection. Journal of Hypertension, 2005, 23, 1273-1275.	0.5	4
195	NADPH oxidase, superoxide overproduction and nitric oxide bioavailability in essential hypertension. Journal of Hypertension, 2005, 23, 665-666.	0.5	7
196	l-Carnitine and erythropoiesis: relationship with haeme oxygenase-1. Nephrology Dialysis Transplantation, 2005, 20, 1769-1770.	0.7	4
197	Diabetes Induces p66shcGene Expression in Human Peripheral Blood Mononuclear Cells: Relationship to Oxidative Stress. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 1130-1136.	3.6	126
198	Aldosterone, Inflammation, and Preeclampsia. Hypertension, 2005, 45, e10.	2.7	4

#	Article	IF	Citations
199	Rho Kinase Inhibition and Vascular Protection: Support From Studies in Bartter and Gitelman Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, e34; author reply e34-5.	2.4	4
200	Angiotensin II Signalling in Bartter???s and Gitelman???s Syndromes. High Blood Pressure and Cardiovascular Prevention, 2005, 12, 17-26.	2.2	21
201	Oxidative stress and profibrotic action of aldosterone. American Journal of Hypertension, 2005, 18, 441-441.	2.0	0
202	Reduced mRNA and Protein Content of Rho Guanine Nucleotide Exchange Factor (RhoGEF) in Bartterâ€™s and Gitelmanâ€™s Syndromes: Relevance for the Pathophysiology of Hypertension. American Journal of Hypertension, 2005, 18, 1200-1205.	2.0	32
203	Aldosterone-mediated endothelial remodeling and oxidative stress. Kidney International, 2005, 68, 1899-1899.	5.2	0
204	Increased Expression of Regulator of G Protein Signaling-2 (RGS-2) in Bartterâ€™s/Gitelmanâ€™s Syndrome. A Role in the Control of Vascular Tone and Implication for Hypertension. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4153-4157.	3.6	106
205	Effect of Manidipine on Gene Expression and Protein Level of Oxidative Stress-Related Proteins: p22phox and HO-1. Journal of Cardiovascular Pharmacology, 2004, 43, 531-538.	1.9	13
206	Effect of Aldosterone and Glycyrrhetinic Acid on the Protein Expression of PAI-1 and p22phox in Human Mononuclear Leukocytes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1973-1976.	3.6	110
207	G-Protein ??3-Subunit Gene C825T Polymorphism and Cardiovascular Risk. High Blood Pressure and Cardiovascular Prevention, 2004, 11, 107-112.	2.2	1
208	Effects of angiotensin II and insulin on ERK1/2 activation in fibroblasts from hypertensive patients*1. American Journal of Hypertension, 2004, 17, 604-610.	2.0	34
209	Regulator of G protein signaling?2 and control of vascular tone in bartter's/gitelman's sydrome. American Journal of Hypertension, 2004, 17, S153-S154.	2.0	0
210	Rho kinase and PAI-1 in Bartter's/Gitelman's syndromes. Journal of Hypertension, 2004, 22, 1963-1969.	0.5	33
211	Vitamin E-coated dialyzers reduce oxidative stress related proteins and markers in hemodialysis - a molecular biological approach. Clinical Nephrology, 2004, 62, 355-361.	0.7	31
212	Licorice from antiquity to the end of the 19th century: applications in medical therapy. Journal of Nephrology, 2004, 17, 337-41.	2.0	4
213	Myocardial function in Bartter's and Gitelman's syndromes. Kidney International, 2003, 64, 366-367.	5.2	7
214	Pseudohyperaldosteronism: Pathogenetic Mechanisms. Critical Reviews in Clinical Laboratory Sciences, 2003, 40, 295-335.	6.1	27
215	Monocyte NADPH Oxidase Subunit p22phoxand Inducible Hemeoxygenase-1 Gene Expressions Are Increased in Type II Diabetic Patients: Relationship with Oxidative Stress. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1753-1759.	3.6	66
216	Oxidative stress-related factors in Bartter's and Gitelman's syndromes: relevance for angiotensin II signalling. Nephrology Dialysis Transplantation, 2003, 18, 1518-1525.	0.7	46

#	Article	IF	Citations
217	Effect of epoetin on HO-1 mRNA level and plasma antioxidants in hemodialysis patients. International Journal of Clinical Pharmacology and Therapeutics, 2003, 41, 187-192.	0.6	32
218	Kidney transplant in Gitelman's syndrome. Report of the first case. Journal of Nephrology, 2003, 16, 144-7.	2.0	15
219	Double urine circulation: importance of pores. Journal of Nephrology, 2003, 16, 958-60.	2.0	0
220	Clinical Significance of Cytokine Determination in Synovial Fluid. Critical Reviews in Clinical Laboratory Sciences, 2002, 39, 63-88.	6.1	43
221	Oxidative Stress in Kidney Transplant Patients With Calcineurin Inhibitorâ€“Induced Hypertension: Effect of Ramipril. Journal of Cardiovascular Pharmacology, 2002, 40, 625-631.	1.9	65
222	Hermann Boerhaave and Lithotomy: What He Thought about It. American Journal of Nephrology, 2002, 22, 290-294.	3.1	8
223	Reduced content of Î± subunit of Gq protein content in monocytes of Bartter and Gitelman syndromes: Relationship with vascular hyporeactivity. Kidney International, 2002, 61, 353-354.	5.2	32
224	Oxidative stress and TGFb in kidney- transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. Clinical Nephrology, 2002, 58, 103-110.	0.7	41
225	Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide. Journal of Nephrology, 2002, 15, 489-96.	2.0	13
226	Analysis of Gq protein alpha subunit mRNA expression in human monocytes: relevance of the purification step. Clinica Chimica Acta, 2001, 309, 13-18.	1.1	2
227	Abnormalities of Gq-mediated cell signaling in Bartter and Gitelman syndromes1*1See Editorial by Warnock, p. 1197. Kidney International, 2001, 60, 882-889.	5.2	46
228	Chronic renal failure, end-stage renal disease, and peritoneal dialysis in Gitelman's syndrome. American Journal of Kidney Diseases, 2001, 38, 165-168.	1.9	50
229	Warm Hepatic Ischemia in Pigs: Effects of L-Arginine and Oligotide Treatment. Journal of Investigative Surgery, 2001, 14, 303-312.	1.3	8
230	Hypomagnesemia and Chondrocalcinosis in Bartterâ€™s and Gitelmanâ€™s Syndrome: Review of the Pathogenetic Mechanisms. American Journal of Nephrology, 2000, 20, 347-350.	3.1	49
231	Physiological relevance of nitric oxide-angiotensin II interplay in the cardiovascular system. Journal of Hypertension, 2000, 18, 351-352.	0.5	3
232	Control of Vascular Tone in the Syndromes of Bartter and Gitelman. Critical Reviews in Clinical Laboratory Sciences, 2000, 37, 503-522.	6.1	22
233	Idiopathic hypercalciuria: O 2 â^' NO relationship and altered bone metabolism. Journal of Endocrinological Investigation, 2000, 23, 78-83.	3.3	3
234	On Progress in the History of Nephrology. American Journal of Nephrology, 1999, 19, 99-100.	3.1	1

#	Article	IF	Citations
235	Water and Its Effects when Drunk Cold. American Journal of Nephrology, 1999, 19, 182-184.	3.1	2
236	Acute effects of moderate dietary protein restriction in patients with idiopathic hypercalciuria and calcium nephrolithiasis. American Journal of Clinical Nutrition, 1999, 69, 267-271.	4.7	101
237	Giovan Battista Morgagni, a Pioneer of Clinical Nephrology. American Journal of Nephrology, 1999, 19, 222-225.	3.1	10
238	Urinary NO2? and NO3? evaluation by an ion chromatography system. Biomedical Chromatography, 1998, 12, 97-98.	1.7	6
239	Constitutive Endothelial Nitric Oxide Synthase (ecNOS) Gene Expression in Human Monocytes. Angiology, 1998, 49, 419-422.	1.8	11
240	Reduced susceptibility to oxidation of low-density lipoprotein in patients with overproduction of nitric oxide (BartterÊ¼s and GitelmanÊ¼s syndrome). Journal of Hypertension, 1998, 16, 1001-1008.	0.5	42
241	Inhibition of furosemide-sensitive cation transport and activation of sodiumâ€“lithium exchange by endogenous circulating factor(s) in BartterÊ¼s and GitelmanÊ¼s syndromes. Journal of Hypertension, 1997, 15, 1407-1413.	0.5	9
242	Increased urinary NO2â^'/NO3â^' and cyclic guanosine monophosphate levels in patients with bartter's syndrome: Relationship to vascular reactivity. American Journal of Kidney Diseases, 1996, 27, 784-789.	1.9	48
243	Intracellular Calcium Signalling and Vascular Reactivity in Bartterâ€™s Syndrome. Nephron, 1996, 72, 570-573.	1.8	25
244	Endothelium-Derived Vasoactive Substances in Bartter's Syndrome. Angiology, 1995, 46, 905-913.	1.8	13
245	Peritoneal Sclerosis: Role of Plasticizers in Stimulating Interleukin-1 Production. Peritoneal Dialysis International, 1993, 13, 517-519.	2.3	13
246	Is hydrochlorothiazide-induced hypocalciuria due to inhibition of prostaglandin E2 synthesis?. Clinical Science, 1990, 78, 321-325.	4.3	13
247	Resting and stimulated cytosolic free calcium levels in neutrophils from patients with Bartter's syndrome. Clinical Science, 1987, 72, 483-488.	4.3	28
248	Arachidonic acid metabolites in a nephroblastoma associated with paraneoplastic hypercalcemia. Prostaglandins, 1986, 32, 116-120.	1.2	2
249	Synthesis and catabolism of PGE2 by a nephroblastoma associated with hypercalcemia without bone metastases. Cancer, 1984, 54, 635-637.	4.1	20
250	Molecular aspects of the altered Angiotensin II signalling in Gitelmanâ€™s syndrome. Expert Opinion on Orphan Drugs, 0, , .	0.8	0
251	The Effect of Green Tea as an Adjuvant to Enzyme Replacement Therapy on Oxidative Stress in Fabry Disease: A Pilot Study. Frontiers in Nutrition, 0, 9, .	3.7	6